Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD Guided Adjuvant Therapy in Renal Cell Carcinoma
NCT06005818Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in renal cell carcinoma (RCC), sponsored by University of Alabama at Birmingham. Started Jan 2024; status: terminated.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06005818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005818.